Macquarie Group Ltd. decreased its holdings in shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) by 1.0% during the second quarter, according to the company in its most recent disclosure with the SEC. The fund owned 247,485 shares of the biotechnology company’s stock after selling 2,501 shares during the quarter. Macquarie Group Ltd. owned 0.18% of Ironwood Pharmaceuticals worth $4,673,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Teacher Retirement System of Texas bought a new position in shares of Ironwood Pharmaceuticals during the second quarter valued at approximately $192,000. Jane Street Group LLC bought a new position in shares of Ironwood Pharmaceuticals during the first quarter valued at approximately $194,000. Strs Ohio grew its stake in shares of Ironwood Pharmaceuticals by 63.1% during the second quarter. Strs Ohio now owns 10,600 shares of the biotechnology company’s stock valued at $200,000 after buying an additional 4,100 shares during the last quarter. Karp Capital Management Corp bought a new position in shares of Ironwood Pharmaceuticals during the first quarter valued at approximately $201,000. Finally, Raymond James Financial Services Advisors Inc. grew its stake in shares of Ironwood Pharmaceuticals by 8.0% during the first quarter. Raymond James Financial Services Advisors Inc. now owns 12,161 shares of the biotechnology company’s stock valued at $207,000 after buying an additional 898 shares during the last quarter. 97.16% of the stock is currently owned by hedge funds and other institutional investors.

IRWD has been the topic of a number of analyst reports. BidaskClub raised Ironwood Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Friday, August 25th. Zacks Investment Research raised Ironwood Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Monday, July 17th. Wells Fargo & Company set a $19.00 target price on Ironwood Pharmaceuticals and gave the company a “buy” rating in a research note on Saturday, July 22nd. Wood & Company cut Ironwood Pharmaceuticals from an “overweight” rating to a “neutral” rating in a research note on Friday, July 21st. Finally, ValuEngine raised Ironwood Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, September 1st. Two investment analysts have rated the stock with a sell rating, five have given a hold rating and four have assigned a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus price target of $18.29.

Shares of Ironwood Pharmaceuticals, Inc. (NASDAQ IRWD) opened at 15.04 on Thursday. The stock’s market cap is $2.25 billion. The company has a 50 day moving average price of $15.90 and a 200-day moving average price of $16.82. Ironwood Pharmaceuticals, Inc. has a one year low of $12.48 and a one year high of $19.94.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last posted its earnings results on Thursday, August 3rd. The biotechnology company reported ($0.28) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.23) by ($0.05). Ironwood Pharmaceuticals had a negative net margin of 52.97% and a negative return on equity of 333.83%. The company had revenue of $65.10 million during the quarter, compared to analyst estimates of $70.00 million. During the same quarter last year, the business posted ($0.16) EPS. The firm’s revenue for the quarter was up 19.7% on a year-over-year basis. Equities analysts predict that Ironwood Pharmaceuticals, Inc. will post ($1.11) earnings per share for the current fiscal year.

WARNING: This article was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this article on another website, it was illegally copied and reposted in violation of U.S. and international trademark & copyright legislation. The correct version of this article can be viewed at https://www.thecerbatgem.com/2017/10/19/macquarie-group-ltd-has-4-67-million-stake-in-ironwood-pharmaceuticals-inc-irwd.html.

Ironwood Pharmaceuticals Profile

Ironwood Pharmaceuticals, Inc is a biotechnology company. The Company is advancing product opportunities in areas of unmet need, including irritable bowel syndrome with constipation (IBS C), and chronic idiopathic constipation (CIC), hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease (uncontrolled GERD), and vascular and fibrotic diseases.

Want to see what other hedge funds are holding IRWD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD).

Institutional Ownership by Quarter for Ironwood Pharmaceuticals (NASDAQ:IRWD)

Receive News & Stock Ratings for Ironwood Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ironwood Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.